Emicizumab use in major orthopedic surgery
- PMID: 31171509
- PMCID: PMC6560352
- DOI: 10.1182/bloodadvances.2019000228
Emicizumab use in major orthopedic surgery
Abstract
Major orthopedic surgery can be performed safely in hemophilia patients with inhibitors receiving emicizumab.
Conflict of interest statement
Conflict-of-interest disclosure: C.D.S. has served on advisory boards from Bayer, Genentech, and Spark Therapeutics. M.V.R. has received research funding from Alnylam, Biomarin, Bioverative, Opko, Sangamo, Takeda, and Spark Therapeutics and served on advisory boards from Alnylam, Bayer, Biomarin, Bioverative, MOGAM, Takeda, and Spark Therapeutics.
References
-
- Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. ; Treatment Guidelines Working Group on behalf of the World Federation of Hemophilia . Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1-e47. - PubMed
-
- Gouw SC, van den Berg HM, Fischer K, et al. ; PedNet and Research of Determinants of INhibitor development (RODIN) Study Group . Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood. 2013;121(20):4046-4055. - PubMed
-
- Teital J, Berntorp E, Collins P, et al. . A systematic approach to controlling problem bleeds in patients with severe congenital hemophilia A and high-titre inhibitors. Haemophilia. 2007;13(3):256-263. - PubMed
-
- Scalone L, Mantovani LG, Mannucci PM, Gringeri A; COCIS Study investigators . Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia. 2006;12(2):154-162. - PubMed
-
- Weyand AC, Pipe SW. New therapies for hemophilia. Blood. 2019;133(5):389-398. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical